Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673933 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Photocure.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00673933: Completed Phase 2 study of Acne Vulgaris, sponsored by Photocure.
NCT00673933 is a Phase 2 study of Acne Vulgaris that has completed, run by Photocure. The registered enrollment target is 20 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00673933, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Photocure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this multicenter study, patients with dark skin and acne vulgaris will be included. The patients will receive treatment with MAL PDT and placebo PDT.
Conditions Studied
Interventions
- DRUG Methyl aminolevulinate (MAL) PDT
Study Locations (2)
Illinois
- DuPage Medical Group - Naperville
New Mexico
- Academic Dermatology Associates - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00673933 record still lists
NCT00673933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Methyl aminolevulinate (MAL) PDT is the first listed.
NCT00673933 reports a single indexed study location in Illinois, New Mexico.
Frequently Asked Questions
What is clinical trial NCT00673933 about?
NCT00673933 is a clinical study titled "Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris". In this multicenter study, patients with dark skin and acne vulgaris will be included. The patients will receive treatment with MAL PDT and placebo PDT.
What is the current status of trial NCT00673933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-05. Estimated completion is 2008-12.
What conditions does trial NCT00673933 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00673933?
The interventions under investigation include: Methyl aminolevulinate (MAL) PDT (DRUG).
Who is sponsoring clinical trial NCT00673933?
This trial is sponsored by Photocure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00673933 being conducted?
This trial has 2 study locations across Illinois, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00673933's enrollment target sits among peer trials
20 62nd of 67 higher than 5 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia